Table 3 s-RNY1-5p level according to high sensitive C-reactive protein (hs-CRP) levels, apolipoprotein B (ApoB) levels, statin therapy, and fibrate therapy and case–control (CC) status
From: RNY-derived small RNAs as a signature of coronary artery disease
CRP (mg/L) | CC | (s-RNY1-5p)1/7 | CC effect | hs-CRP effect | CC × hs-CRP interaction |
<6 | Case (n = 121) | 1.30 (0.17) | 0.001 | 0.03 | 0.72 |
≥6 | Case (n = 142) | 1.34 (0.18) | |||
<6 | Control (n = 449) | 0.95 (0.18) | |||
≥6 | Control (n = 65) | 0.98 (0.20) | |||
ApoB (g/L) | CC | (s-RNY1-5p)1/7 | CC effect | ApoB effect | CC × ApoB interaction |
<1.02 | Case (n = 115) | 1.30 (0.18) | 0.001 | 0.001 | 0.79 |
≥1.02 | Case (n = 148) | 1.35 (0.17) | |||
<1.02 | Control (n = 200) | 0.92 (0.19) | |||
≥1.02 | Control (n = 314) | 0.97 (0.19) | |||
Statin therapy | CC | (s-RNY1-5p)1/7 | CC effect | statin effect | CC × statin interaction |
No | Case (n = 115) | 1.34 (0.18) | 0.001 | 0.15 | 0.78 |
Yes | Case (n = 148) | 1.31 (0.18) | |||
No | Control (n = 428) | 0.95 (0.19) | |||
Yes | Control (n = 86) | 0.93 (0.20) | |||
Fibrate therapy | CC | (s-RNY1-5p)1/7 | CC effect | fibrate effect | CC × fibrate interaction |
No | Case (n = 242) | 1.33 (0.17) | 0.001 | 0.21 | 0.46 |
Yes | Case (n = 21) | 1.28 (0.19) | |||
No | Control (n = 472) | 0.95 (0.19) | |||
Yes | Control (n = 42) | 0.94 (0.18) |